Application No. 09/743,781 Paper Dated January 27, 2004 Reply to USPTO Correspondence of October 27, 2003 Attorney Docket No. 4303-030806

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

## **Listing of Claims**

- 1. (currently amended): A method of modifying <u>beta-amyloid-induced</u> vasoactivity <u>in individuals with Alzheimer's Disease or related disorders</u>, comprising <del>regulating</del> a <u>soluble A\$ antagonizing the phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2</u> pro-inflammatory pathway <u>by administering a pharmaceutically effective amount of</u> a phospholipase A2 inhibitor to the individual.
- 2. (previously presented): The method according to claim 1, further defined as upregulating the soluble  $A\beta$  pro-inflammatory pathway.
- 3. (previously presented): The method according to claim 1, further defined as down-regulating the soluble  $A\beta$  pro-inflammatory pathway.

4-21. (canceled)